TY - JOUR
T1 - The effect of a hysteroscopic niche resection compared with Levonorgestrel-releasing intrauterine device on postmenstrual spotting in patients with a symptomatic niche in the uterine cesarean scar: A prospective cohort study
AU - He, Xiaoqing
AU - Yan, Li
AU - He, Chuqing
AU - Zhu, Chenfeng
AU - Mol, Ben W.
AU - Zhang, Jian
AU - Huirne, J. A. F.
N1 - Funding Information:
This work was supported by National Key Research and Development Program (grant number 2018YFC1002102), Clinical Research Project of Shanghai Health and Fitness Commission (201940012), Shanghai Municipal Key Clinical Specialty (shslczdzk01802), Scientific Research Project of Shanghai Health and Fitness Commission (20184Y0344), International Peace Maternal and Child Health Institute Clinical Research Program (GFY5826), and Medical Engineering Cross Youth Funds from Shanghai Jiao Tong University (YG2017QN38), Translational Medicine Cross Fund from Shanghai Jiao Tong University (ZH2018QNA36), Medical innovation research project of the 2020 “Science and Technology Innovation Action Plan” of Shanghai Science and Technology Commission (20Y11907700), Clinical Science and Technology Innovation Project of Shanghai Hospital Development Center (SHDC22020216), Star of Shanghai Jiaotong University Science and Technology Innovation Special Project (YG2021ZD31), Shanghai Municipal Health and Family Planning Commission (20184Y0344).
Publisher Copyright:
© 2021 Elsevier B.V.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Objective: To compare the effect of a hysteroscopic niche resection with a Levonorgestrel-releasing intrauterine device (LNG-IUD, 52 mg) on postmenstrual spotting duration in patients with a symptomatic niche in the uterine cesarean scar. Study design: This prospective cohort study was conducted at the International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University, China. Patients with postmenstrual spotting symptomatic niches were allocated to hysteroscopy group or LNG-IUD group based on the shared medical decision-making approach, and were followed up for 1 year after treatment. Main outcome measures: The primary outcome was reduced postmenstrual spotting days at 6th month after treatment. Secondary outcomes were effectiveness rate (proportion of patients with spotting days reduced by at least 50% from baseline), menstrual characteristics, menstruation satisfaction, direct medical costs, complications and side effects. Results: 78 out of the 82 eligible patients were included, 36 patients in both group finished 1-year follow-up. Reduced spotting days at the 6th month was 7 days in LNG-IUD group, significantly higher than 5 days in hysteroscopy group, P = 0.004; The effectiveness rate increased over time within 1 year after the insertion of LNG-IUD (63.89%, 83.33%, 88.89%, 88.89%, P for trend = 0.006), while no trend change was observed in hysteroscopy group (71.05%, 71.05%, 66.67%, 61.11%, P for trend = 0.77). The mean direct medical costs were 817[785,856] $ in the hysteroscopy group and 243[239,255] $ in the LNG-IUD group (p<0.001). 2 patients removed IUD and 2 patients reported weight gain of more than 5 kg and breast distended pain in LNG-IUD group; 2 patients got pregnant in hysteroscopy group. No serious complications were observed in both groups. Conclusions: LNG-IUD is more effective in the treatment of postmenstrual spotting from the 6th month onwards than a hysteroscopic niche resection in patients with a symptomatic niche at lower direct costs.
AB - Objective: To compare the effect of a hysteroscopic niche resection with a Levonorgestrel-releasing intrauterine device (LNG-IUD, 52 mg) on postmenstrual spotting duration in patients with a symptomatic niche in the uterine cesarean scar. Study design: This prospective cohort study was conducted at the International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University, China. Patients with postmenstrual spotting symptomatic niches were allocated to hysteroscopy group or LNG-IUD group based on the shared medical decision-making approach, and were followed up for 1 year after treatment. Main outcome measures: The primary outcome was reduced postmenstrual spotting days at 6th month after treatment. Secondary outcomes were effectiveness rate (proportion of patients with spotting days reduced by at least 50% from baseline), menstrual characteristics, menstruation satisfaction, direct medical costs, complications and side effects. Results: 78 out of the 82 eligible patients were included, 36 patients in both group finished 1-year follow-up. Reduced spotting days at the 6th month was 7 days in LNG-IUD group, significantly higher than 5 days in hysteroscopy group, P = 0.004; The effectiveness rate increased over time within 1 year after the insertion of LNG-IUD (63.89%, 83.33%, 88.89%, 88.89%, P for trend = 0.006), while no trend change was observed in hysteroscopy group (71.05%, 71.05%, 66.67%, 61.11%, P for trend = 0.77). The mean direct medical costs were 817[785,856] $ in the hysteroscopy group and 243[239,255] $ in the LNG-IUD group (p<0.001). 2 patients removed IUD and 2 patients reported weight gain of more than 5 kg and breast distended pain in LNG-IUD group; 2 patients got pregnant in hysteroscopy group. No serious complications were observed in both groups. Conclusions: LNG-IUD is more effective in the treatment of postmenstrual spotting from the 6th month onwards than a hysteroscopic niche resection in patients with a symptomatic niche at lower direct costs.
KW - Hysteroscopy niche resection
KW - Levonorgestrel-releasing intrauterine device
KW - Niche
KW - Postmenstrual spotting
KW - Uterine cesarean scar
UR - http://www.scopus.com/inward/record.url?scp=85113444669&partnerID=8YFLogxK
U2 - 10.1016/j.ejogrb.2021.08.014
DO - 10.1016/j.ejogrb.2021.08.014
M3 - Article
C2 - 34461384
VL - 265
SP - 66
EP - 73
JO - European Journal of Obstetrics and Gynecology and Reproductive Biology
JF - European Journal of Obstetrics and Gynecology and Reproductive Biology
SN - 0301-2115
ER -